



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Rezdifra (resmetirom)	Page: 1 of 2
Effective Date: 1/1/2026	Last Review Date: 9/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Rezdifra under the patient's prescription drug benefit.

### Description:

#### FDA-Approved Indications

Rezdifra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

This indication is approved under accelerated approval based on improvement of NASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

#### Limitations of Use

Avoid use of Rezdifra in patients with decompensated cirrhosis.

### Applicable Drug List:

Rezdifra

### Policy/Guideline:

#### Coverage Criteria:

#### Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

Authorization may be granted when the requested drug is being prescribed for the treatment of an adult patient with noncirrhotic nonalcoholic steatohepatitis (NASH) [i.e., metabolic dysfunction-associated steatohepatitis (MASH)] with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) at baseline when ALL of the following criteria are met:

- The requested drug will be used in conjunction with diet and exercise.
- The requested drug is being prescribed by, or in consultation with, a gastroenterologist or hepatologist.
- The patient's moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) at baseline has been confirmed by ONE of the following: non-invasive liver disease assessment (e.g., ultrasound-based elastography, magnetic resonance elastography [MRE]) OR historical liver biopsy. [ACTION REQUIRED: Documentation is required for approval.]



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name:	Rezdiffra (resmetirom)	Page:	2 of 2
Effective Date:	1/1/2026	Last Review Date:	9/2025
Applies to:	<input checked="" type="checkbox"/> Illinois <input checked="" type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input checked="" type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Kentucky PRMD

## Continuation of Therapy

### Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

Authorization may be granted when the requested drug is being prescribed for an adult patient with noncirrhotic nonalcoholic steatohepatitis (NASH) [i.e., metabolic dysfunction-associated steatohepatitis (MASH)] with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) when ALL of the following criteria are met:

- The requested drug will be used in conjunction with diet and exercise.
- The patient has achieved or maintained a positive clinical response to the requested drug (e.g., improvement in liver function such as reduction in alanine aminotransferase [ALT], improvement in Enhanced Liver Fibrosis (ELF) score, improvement in liver stiffness measurement [LSM] by ultrasound-based elastography, magnetic resonance elastography [MRE]). [ACTION REQUIRED: Documentation is required for approval.]

### Approval Duration and Quantity Restrictions:

**Initial Approval:** 12 months

**Renewal Approval:** 12 months

**Quantity Level Limit:** Reference Formulary for drug specific quantity level limits

### References:

1. Rezdiffra [package insert]. West Conshohocken, PA: Madrigal Pharmaceuticals, Inc.; March 2024.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed March 12, 2025.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 03/12/2025).
4. Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. *Hepatology*. 2025;81(1):312-320.
5. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology* 2023;77(5): 1797-1835.